Fewer Prescriptions, More Resistance: The Troubling Disconnect in Azithromycin's Public Health Story
For more than a decade, the guiding principle of antibiotic stewardship has been elegantly simple: prescribe less, and resistance will follow downward. It is an intuitive framework, and for many drug classes, it has shown measurable results. Azithromycin, however, is increasingly defying that logic. Across multiple bacterial species and in multiple regions of the United States, resistance rates continue to climb even as annual prescription volumes trend downward. The gap between what stewardship models predict and what surveillance data actually shows has become too wide to ignore.
This is not an argument against reducing unnecessary prescriptions. That effort remains critically important. Rather, it is an acknowledgment that the relationship between prescribing behavior and resistance development is far more complex than any single-variable model can capture—and that patients, clinicians, and policymakers need a more complete picture to make meaningful progress.
The Numbers That Don't Add Up
Azithromycin prescribing in the United States peaked in the mid-2000s and again during the early years of the COVID-19 pandemic, when off-label use surged despite limited clinical evidence of benefit. Since then, prescriptions have declined in several outpatient settings, driven by updated clinical guidelines, increased physician awareness of resistance concerns, and institutional stewardship programs at hospitals and health systems nationwide.
Yet surveillance data from the Centers for Disease Control and Prevention and independent academic research tell a more complicated story. Resistance among Neisseria gonorrhoeae—one of the pathogens for which azithromycin was once a cornerstone treatment—has risen so sharply that the drug has been effectively removed from first-line gonorrhea treatment protocols. Resistance rates in Streptococcus pneumoniae and Mycoplasma pneumoniae have also increased in certain geographic clusters, even in communities where outpatient macrolide use has declined. The drug's own therapeutic legacy appears to be outlasting its current prescription footprint.
Why Resistance Persists After Prescriptions Fall
Several mechanisms help explain this counterintuitive trajectory.
The reservoir effect of prior overuse. Resistance is not erased when prescribing stops. Resistant bacterial strains already circulating in a population continue to spread through person-to-person transmission, community contact, and healthcare settings. The genetic adaptations that allow bacteria to survive azithromycin exposure can persist in microbial populations for years—sometimes decades—after the original selective pressure is reduced. In essence, the resistance that was generated during peak prescribing years has not simply dissolved; it has become embedded in local bacterial ecosystems.
Incomplete treatment courses. When patients stop taking azithromycin before completing the prescribed regimen—whether due to symptom resolution, side effects, cost barriers, or simple forgetfulness—they may leave partially suppressed bacterial populations intact. These surviving organisms are disproportionately likely to carry or develop resistance traits. Even a five-day Z-Pack course, shorter than many antibiotic regimens, creates opportunity for incomplete bacterial clearance if adherence is inconsistent.
Agricultural and environmental exposure. This dimension of the resistance problem receives far less public attention than it deserves. Macrolide antibiotics, including azithromycin and its chemical relatives, are used in livestock production in the United States. Resistant bacteria and resistance genes from agricultural environments can enter human populations through food supply chains, water contamination, and direct contact. Research published in peer-reviewed journals has documented the transmission of macrolide-resistant organisms from animal reservoirs to human communities, complicating any analysis that focuses exclusively on clinical prescribing data.
International travel and importation. The United States does not exist in a microbiological vacuum. Travelers returning from regions with higher macrolide resistance rates—parts of Asia, for instance, where macrolide-resistant Mycoplasma pneumoniae is particularly prevalent—can introduce resistant strains into domestic bacterial populations. Urban centers and communities with high international travel volumes may therefore show resistance patterns that diverge significantly from national averages, regardless of local prescribing habits.
Regional Variation Across the United States
One of the most clinically significant aspects of the azithromycin resistance landscape is how unevenly it is distributed across the country. Resistance rates for specific pathogens can vary substantially between states, between urban and rural settings, and even between neighboring counties served by different healthcare systems.
Southeastern states, for instance, have historically shown higher rates of macrolide-resistant S. pneumoniae compared to some Western and Midwestern regions, a pattern that researchers have linked to both historical prescribing practices and demographic factors influencing antibiotic access and use. Urban centers with dense populations and high rates of sexually transmitted infections have borne a disproportionate share of the gonorrhea resistance burden. Rural communities, meanwhile, may face different resistance pressures related to agricultural proximity and limited access to the diagnostic infrastructure that enables targeted prescribing.
This regional heterogeneity has significant implications for clinical decision-making. A physician in one part of the country may be operating under a very different local resistance landscape than a colleague practicing in another region, even when both are following the same national guidelines. Local antibiograms—systematic reports of resistance patterns compiled by hospital laboratories and public health agencies—are therefore an essential tool that remains underutilized in many outpatient settings.
Rethinking What Stewardship Actually Means
The azithromycin resistance paradox is, at its core, a challenge to the reductive version of antibiotic stewardship that equates responsible use with simply prescribing less. Volume reduction is a necessary but insufficient condition for resistance control. Effective stewardship must also address the quality of prescribing—ensuring that when azithromycin is prescribed, it is prescribed for the right indication, at the correct dose, for the appropriate duration, and to a patient who will complete the course.
It must also extend beyond the clinical encounter. Policies governing agricultural antibiotic use, environmental monitoring of resistance genes in water systems, international coordination on surveillance and reporting, and public education about the biological persistence of resistance all belong under the stewardship umbrella. A framework that focuses exclusively on the prescription pad will continue to produce incomplete results.
For patients currently prescribed azithromycin, the practical implications are straightforward: complete the full course as directed, even if symptoms resolve early; do not share medication or save unused doses for future use; and communicate openly with your prescriber about any factors—cost, side effects, scheduling—that might interfere with adherence. These individual behaviors, multiplied across millions of patients, have a measurable collective impact on resistance trajectories.
The Road Ahead
Azithromycin remains a clinically valuable antibiotic for a range of bacterial infections, and its unique pharmacokinetic profile continues to make it a practical option in outpatient settings. But its long-term utility depends on a clearer-eyed understanding of resistance dynamics—one that acknowledges the limits of prescription volume as a proxy for stewardship success.
Public health agencies, clinicians, researchers, and patients all have a role to play in addressing the forces that allow resistance to persist and spread even in the absence of new antibiotic pressure. The data suggest that those forces are more numerous, more durable, and more geographically variable than simplified stewardship models have historically accounted for. Confronting that complexity honestly is the necessary first step toward more effective solutions.
